News | Stents Bioresorbable | August 05, 2015

Global Bioabsorbable Scaffolds Market to Pass $2 Billion by 2021

GlobalData report suggests BAS could become the new standard for coronary and peripheral artery disease stenting over drug-eluting stents

bioabsorbable scaffolds, BAS, global market, 2021, 10MM, 5EU, GlobalData

Absorb BVS image courtesy of Abbott

August 5, 2015 — The global market value for bioabsorbable scaffolds (BAS) will expand rapidly from $143.7 million in 2014 to just under $2.1 billion by 2021, said research and consulting firm GlobalData. The surge will be driven primarily by new product approvals and a paradigm shift in the clinical treatment of vascular diseases towards minimally-invasive procedures.

GlobalData’s latest report states that this significant increase — which will occur across the 10 major markets (10MM) of the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, China, and India — represents an impressive compound annual growth rate (CAGR) of 42.1 percent.

Amen Sanghera, GlobalData’s analyst covering medical devices, said that while BAS devices have yet to gain regulatory approval in the United States, China and Japan, there are already four CE-marked BAS devices approved in the five European countries (5EU).

Sanghera commented: “Abbott Vascular is the primary player in this market with its drug-eluting BAS, Absorb BVS, which is available across the 5EU and in selected Latin-American and Asian countries. The product is expected to gain U.S. Food and Drug Administration approval by 2016.

“Abbott Vascular recently gained the CE mark for a package incorporating both Absorb BVS and the company’s state-of-the-art catheter delivery system, the GlideTrack. This package is expected to increase the uptake of the Absorb BVS system, as it addresses clinical concerns surrounding the delivery of its device to occluded coronary vessels.”

With sufficient improvements, GlobalData anticipates that BAS could begin to challenge drug-eluting stents as the gold standard of coronary and peripheral artery disease stenting, as BAS devices aim to directly confront the current issues with permanent metallic stents, such as late in-stent restenosis, vessel scarring and late stent thrombosis.

Sanghera continued: “Technological trends in the market are aimed at reducing the thickness of BAS and providing better delivery systems, more efficient drug-elution characteristics and faster resorption times.

“As long-term clinical data demonstrating their efficacy become available, the uptake of BAS will gradually increase across the 10MM. The expanding presence of BAS products, along with a reduction in their prices, will drive substantial growth during the forecast period,” the analyst concluded.

For more information: www.globaldata.com

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init